Clinical Trial Update: A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) [Phase 3]

View source ↗

Summary

A phase 3b, single-arm study evaluating aflibercept 8 mg every 4 weeks in adults with neovascular age-related macular degeneration or diabetic macular edema is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 3 | Status: ACTIVE_NOT_RECRUITING